Logo image of REUN

REUNION NEUROSCIENCE INC (REUN) Stock Fundamental Analysis

USA - NASDAQ:REUN - CA76134G1037 - Common Stock

1.12 USD
-0.01 (-0.88%)
Last: 7/31/2023, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to REUN. REUN was compared to 536 industry peers in the Biotechnology industry. While REUN seems to be doing ok healthwise, there are quite some concerns on its profitability. REUN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

REUN had negative earnings in the past year.
REUN had a negative operating cash flow in the past year.
In the past 5 years REUN always reported negative net income.
REUN had a negative operating cash flow in each of the past 5 years.
REUN Yearly Net Income VS EBIT VS OCF VS FCFREUN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

REUN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REUN Yearly ROA, ROE, ROICREUN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

REUN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REUN Yearly Profit, Operating, Gross MarginsREUN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for REUN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
REUN Yearly Shares OutstandingREUN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
REUN Yearly Total Debt VS Total AssetsREUN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.82, we must say that REUN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of REUN (-4.82) is worse than 68.31% of its industry peers.
REUN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.82
ROIC/WACCN/A
WACCN/A
REUN Yearly LT Debt VS Equity VS FCFREUN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 3.52 indicates that REUN has no problem at all paying its short term obligations.
REUN has a worse Current ratio (3.52) than 66.95% of its industry peers.
REUN has a Quick Ratio of 3.52. This indicates that REUN is financially healthy and has no problem in meeting its short term obligations.
REUN's Quick ratio of 3.52 is on the low side compared to the rest of the industry. REUN is outperformed by 65.59% of its industry peers.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 3.52
REUN Yearly Current Assets VS Current LiabilitesREUN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.96% over the past year.
REUN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)86.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.8%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, REUN will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.87% on average per year.
REUN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 157.08% yearly.
EPS Next Y47.21%
EPS Next 2Y35.9%
EPS Next 3Y21.92%
EPS Next 5Y13.87%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y157.08%

3.3 Evolution

REUN Yearly Revenue VS EstimatesREUN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2028 2029 2030 100M 200M 300M 400M 500M
REUN Yearly EPS VS EstimatesREUN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for REUN. In the last year negative earnings were reported.
Also next year REUN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REUN Price Earnings VS Forward Price EarningsREUN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REUN Per share dataREUN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as REUN's earnings are expected to grow with 21.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.9%
EPS Next 3Y21.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for REUN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REUNION NEUROSCIENCE INC

NASDAQ:REUN (7/31/2023, 8:00:01 PM)

1.12

-0.01 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-29 2023-06-29/amc
Earnings (Next)N/A N/A
Inst Owners2.32%
Inst Owner Change-84.34%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.12M
Analysts80
Price Target130.02 (11508.93%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-55.47%
Min EPS beat(2)-135.74%
Max EPS beat(2)24.8%
EPS beat(4)2
Avg EPS beat(4)-47.95%
Min EPS beat(4)-176.11%
Max EPS beat(4)95.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-2.33
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-1.79
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0
BVpS1.35
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 3.52
Altman-Z -4.82
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)73.49%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.8%
EPS Next Y47.21%
EPS Next 2Y35.9%
EPS Next 3Y21.92%
EPS Next 5Y13.87%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y157.08%
EBIT growth 1Y41.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.73%
EBIT Next 3Y-43.57%
EBIT Next 5Y-12.46%
FCF growth 1Y40.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.93%
OCF growth 3YN/A
OCF growth 5YN/A